Trump announces trade deal with EU following months of negotiations
BOSTON - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC), a clinical-stage biotherapeutics company, is slated to participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. The company’s CEO, Bharatt Chowrira, PhD, JD, alongside Co-founder and President, Eric Elenko, PhD, will discuss PureTech’s pipeline and advancements in biotherapeutics.
The presentation aims to provide insights into PureTech’s research and development efforts, which have yielded 29 therapeutic candidates, including three FDA-approved drugs. The company’s R&D engine, supported by an extensive network of scientists and industry experts, focuses on creating new classes of medicine to treat devastating diseases.
The webcast of the PureTech presentation will be accessible for interested parties at the company’s investor relations website.
PureTech’s approach to drug development involves both internal advancement and collaboration through its Founded Entities, with several programs in various stages of clinical development, including registration-enabling studies.
The company emphasizes that statements regarding its future prospects and strategies are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially from current expectations. These include factors detailed under "Risk Factors" in PureTech’s Annual Report on Form 20-F for the year ended December 31, 2023, and other regulatory filings.
This engagement at the Leerink Partners conference represents an opportunity for PureTech to showcase its contribution to the healthcare sector and its commitment to addressing unmet medical needs through innovative therapeutics.
The information in this article is based on a press release statement from PureTech Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.